Curve Biosciences, Inc.
Formerly Canary Biosciences, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2024 | $18 M | No. 1 | $10 to $50 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Curve Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (May 2024).
SEC Form D · May 2024
The industry group it chose in its notices: Other.
SEC Form D · May 2024
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Curve Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Chuba Oyolu | Executive officer | May 2024 |
| Nathan Hunkapiller | Executive officer | May 2024 |
| Ritish Patnaik | Executive officer | May 2024 |
| Shan Xiang Wang | Executive officer | May 2024 |
| Ritish Patnaik | Director | May 2024 |
| Shan Xiang Wang | Director | May 2024 |
| Themasap Khan | Director | May 2024 |